Tuesday, March 11, 2014 4:49:04 PM
ImmuCell Announces Increase in Product Sales and Other Annual Financial Results
.
Marketwired
ImmuCell Corporation
February 13, 2014 8:00 AM
.
.
..
.
.
PORTLAND, ME--(Marketwired - Feb 13, 2014) - ImmuCell Corporation (NASDAQ: ICCC) today announced the results of its operations for the three-month and twelve-month periods ended December 31, 2013.
During the three-month period ended December 31, 2013, product sales increased by 9.7%, or $138,000, to $1,559,000 in comparison to $1,421,000 during the same period in 2012. During the twelve-month period ended December 31, 2013, product sales increased by 11.5%, or $617,000, to $6,007,000 in comparison to $5,390,000 during the same period in 2012.
"We have now increased product sales during the last six consecutive quarters and for twelve of the last thirteen quarters. Sales of First Defense® and related product line extensions increased by 16.5% during the fourth quarter and 14.4% during the year ended December 31, 2013," commented Michael F. Brigham, President and CEO.
The net operating (loss) was ($210,000) during the three-month period ended December 31, 2013, in contrast to a net operating income of $12,000 during the same period in 2012. The net (loss) was ($151,000), or ($0.05) per share, during the three-month period ended December 31, 2013, in comparison to a net (loss) of ($17,000), or ($0.01) per share, during the same period in 2012.
Net operating (loss) was ($20,000) during the twelve-month period ended December 31, 2013, in contrast to net operating income of $245,000 during the same period in 2012. Net income was $117,000, or $0.04 per share, during the twelve-month period ended December 31, 2013, in comparison to net income of $90,000, or $0.03 per share, during the same period in 2012.
Regarding the fourth quarter loss, Mr. Brigham added, "During the fourth quarter, we incurred approximately $110,000 in expenses as we initiated our planned investment in a Nisin production plant for Mast Out®. Further, we reduced production output during the last six months of 2013 in order to replace and repair certain pieces of critical process equipment, which resulted in an increase in cost of goods sold. We expect our gross margin percentage to be more in line with our historical norms during 2014."
Cash, cash equivalents and short-term investments increased by 7%, or $342,000, to $5,255,000 as of December 31, 2013, in comparison to $4,914,000 as of December 31, 2012. Stockholders' equity increased by 2%, or $201,000, to $9,396,000 as of December 31, 2013, in comparison to $9,195,000 as of December 31, 2012. The Company had 3,026,000 shares of common stock outstanding as of December 31, 2013.
(Unaudited)
For the Three-Month Periods Ended December 31, For the Twelve-Month Periods Ended December 31,
(In thousands, except per share amounts) 2013 2012 2013 2012
Product sales $ 1,559 $ 1,421 $ 6,007 $ 5,390
Costs of goods sold 951 671 2,947 2,336
Gross margin 608 750 3,060 3,054
Product development expenses 325 234 1,154 918
Selling and administrative expenses 493 503 1,926 1,891
Operating expenses 818 737 3,080 2,809
NET OPERATING (LOSS) INCOME (210 ) 13 (20 ) 245
Other (expenses) revenues, net (43 ) (24 ) 225 (53 )
(LOSS) INCOME BEFORE INCOME TAXES (253 ) (11 ) 205 192
Income tax (benefit) expense (102 ) 6 88 102
NET (LOSS) INCOME $ (151 ) $ (17 ) $ 117 $ 90
Weighted average common shares outstanding:
Basic 3,021 3,019 3,019 3,018
Diluted 3,021 3,019 3,085 3,108
NET (LOSS) INCOME PER SHARE:
Basic $ (0.05 ) $ (0.01 ) $ 0.04 $ 0.03
Diluted $ (0.05 ) $ (0.01 ) $ 0.04 $ 0.03
(In thousands) As of December 31, 2013 As of December 31, 2012
Cash, cash equivalents and short-term investments $ 5,255 $ 4,914
Total assets 10,961 11,030
Net working capital 6,632 6,697
Stockholders' equity $ 9,396 $ 9,195
About ImmuCell: ImmuCell Corporation's (NASDAQ: ICCC) purpose is to create scientifically-proven and practical products that result in a measurable economic impact on animal health and productivity in the dairy and beef industries. Press releases and other information about the Company are available at our web-site, (http://www.immucell.com).
Contact:
Michael F. Brigham
President and CEO
(207) 878-2770 Ext. 3106
Recent ICCC News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/24/2024 03:55:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/24/2024 12:31:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/24/2024 12:30:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/24/2024 12:30:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/24/2024 12:29:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/24/2024 12:29:32 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 09/17/2024 05:49:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 04:25:45 PM
- Form SC 13D - General Statement of Acquisition of Beneficial Ownership • Edgar (US Regulatory) • 08/27/2024 08:32:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2024 07:00:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/22/2024 05:05:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/19/2024 05:04:06 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:05:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 08:05:29 PM
- ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2024 • GlobeNewswire Inc. • 08/13/2024 08:05:00 PM
- ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2024 • GlobeNewswire Inc. • 08/07/2024 08:05:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/09/2024 08:05:09 PM
- ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 2024 • GlobeNewswire Inc. • 07/09/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 05:38:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 03:33:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 11:49:43 AM
- ImmuCell Provides Update on Regulatory Status of Product Development Initiative for Re-Tain® • GlobeNewswire Inc. • 06/05/2024 08:05:00 PM
- ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders • GlobeNewswire Inc. • 06/04/2024 08:05:00 PM
- Form SCHEDULE 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 05/22/2024 08:50:57 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:06:15 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM